NEW YORK (GenomeWeb) – Swiss contract research firm Intomics said today that it has inked an agreement to collaborate with Actelion Pharmaceuticals on research into neurodegenerative diseases.

Intomics said that the partners will apply a systems biology approach to gain a better understanding of the pathological processes underlying human neurodegenerative diseases at the molecular level with a long-term goal of facilitating better treatments for patients with such diseases.

Terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.